Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $26.29 Analyst target: $46.38 Upside: 76.42%
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.